Literature DB >> 2521547

Clinical pharmacology of mivacurium chloride (BW B1090U) in children during nitrous oxide-halothane and nitrous oxide-narcotic anesthesia.

J B Sarner1, B W Brandom, S K Woelfel, M L Dong, M C Horn, D R Cook, B F McNulty, V J Foster.   

Abstract

We determined the dose-response relationships of mivacurium (BW B1090U) in children (2-10 years) during nitrous oxide-halothane anesthesia (0.8% end-tidal) and during nitrous oxide-narcotic anesthesia. Neuromuscular blockade was monitored by recording the electromyographic activity of the adductor pollicis muscle resulting from supramaximal stimulation at the ulnar nerve at 2 Hz for 2 seconds at 10-second intervals. To estimate dose-response relationships, for each anesthetic background four subgroups of nine patients received single bolus doses of 20-120 micrograms/kg mivacurium. The ED50 and ED95 (estimated from linear regression plots of log-dose vs. probit of effect) were 52 micrograms/kg and 89 micrograms/kg during halothane anesthesia and 62 micrograms/kg and 103 micrograms/kg during narcotic anesthesia. Nine additional patients in each anesthetic group received 250 micrograms/kg mivacurium. Three of the 18 patients given 250 micrograms/kg mivacurium developed cutaneous flushing; in one of these mean arterial pressure decreased 32% for less than 1 minute; no significant changes in heart rate occurred. With the increase in mivacurium dose from 120 micrograms/kg to 250 micrograms/kg the times to onset of 90% and maximum neuromuscular block decreased by 0.5 to 1 minute, and the times to recovery of neuromuscular transmission to 5% (T5) or 25% (T25) increased by 2-4 minutes. The recovery index (T25-75) in patients anesthetized with halothane was 4.3 +/- 1.5 minute (mean +/- SD); the time to complete recovery (T4:1 greater than or equal to 0.75) was 19.8 +/- 7.4 minutes.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2521547     DOI: 10.1213/00000539-198902000-00009

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  5 in total

1.  Neuromuscular and cardiovascular effects of mivacurium chloride in surgical patients receiving nitrous oxide-narcotic or nitrous oxide-isoflurane anaesthesia.

Authors:  W W Choi; M P Mehta; D J Murray; M D Sokoll; R B Forbes; S D Gergis; M Abou-Donia; J Kirchner
Journal:  Can J Anaesth       Date:  1989-11       Impact factor: 5.063

Review 2.  Newer neuromuscular blocking drugs. An overview of their clinical pharmacology and therapeutic use.

Authors:  R K Mirakhur
Journal:  Drugs       Date:  1992-08       Impact factor: 9.546

Review 3.  Mivacurium. A review of its pharmacology and therapeutic potential in general anaesthesia.

Authors:  James E Frampton; Donna McTavish
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

4.  Mivacurium-induced neuromuscular blockade during sevoflurane and halothane anaesthesia in children.

Authors:  R F Kaplan; M Garcia; R S Hannallah
Journal:  Can J Anaesth       Date:  1995-01       Impact factor: 5.063

5.  Effect of mivacurium 200 and 250 &mgr;g/kg in infants during isoflurane anesthesia: a randomized controlled trial [ISRCTN07742712].

Authors:  Alejandro A Nava-Ocampo; Ferel T Aguirre-Garay; Elvia Y Velázquez-Armenta; Diana Moyao-García
Journal:  BMC Anesthesiol       Date:  2001       Impact factor: 2.217

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.